TECENTRIQ subkutan 1875 mg/15ml, Injektionslösung zur subkutanen Anwendung

7680692620019 CH-69262 Injektionslösung zur subkutanen Anwendung
TECENTRIQ subkutan 1875 mg/15ml, Injektionslösung zur subkutanen Anwendung
TECENTRIQ subkutan 1875 mg/15ml, Injektionslösung zur subkutanen Anwendung
1 / 2
google

Article details

Package size
1
Selling units
1
Measure
Durchstechflasche(n)
Galenic form
Injektionslösung zur subkutanen Anwendung
Galenic group
unbekannt

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
04/10/2024
Summary of Product Characteristics
Français
04/10/2024
Summary of Product Characteristics
Italien
04/10/2024

Detailed composition

Substance Quantity Type Category
(N/A)
1875.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK

Reimbursement information

Public price
CHF 4221.55
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/11/2024

Authorization holder

Roche Pharma (Schweiz) AG

4058 Basel

Authorization information

Swissmedic authorization number
69262
Drug name
TECENTRIQ subkutan, Injektionslösung
Galenic form
LSINJ
ATC Code
L01FF05
Authorization status
Z
Dispensing category
A
First authorization
05/08/2024
Authorization expiration date
04/08/2029
IT Number
07.16.1.
Domain
Human medicine
Field of application
Onkologikum

Package details

Description (FR)
TECENTRIQ sous-cutané sol inj 1875 mg/15 ml flac
Description (DE)
TECENTRIQ subkutan Inj Lös 1875 mg/15 ml Durchstf
Market launch
05/08/2024
Narcotic (BTM)
No